Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VJOncology

- PMLiVE

J&J’s subcutaneous Darzalex regimen approved by EC for newly diagnosed multiple myeloma

More than 35,000 people in the EU were diagnosed with the blood cancer in 2022

- PMLiVE

Amgen shares positive phase 3 results for Imdelltra in small cell lung cancer

The aggressive lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

Point.1: Your first point in people-centred precision marketing

By Phil Streit

- PMLiVE

AstraZeneca’s Truqap recommended by NICE to treat advanced breast cancer

NICE estimates that around 1,100 patients will benefit from the twice-a-day tablet

- PMLiVE

BMS receives FDA approval for immunotherapy combination in liver cancer

Around 42,240 people are expected to be diagnosed with liver cancer in the US this year

- PMLiVE

Roche’s Columvi granted EC approval to treat diffuse large B-cell lymphoma

Approximately 38,000 people are diagnosed with DLBCL every year in Europe

- PMLiVE

How HCPs and patients are partnering to transform care

Equipping patients, carers and loved ones with the tools and understanding to make the choices that are right for them through shared decision-making

- PMLiVE

11 London and B Corp

Three years ago, 11 London became the first UK health agency to gain B-Corp accreditation. CEO and Co-Founder, Matt Hunt reports back on life in the B-List...

11 London

Beyond The Hype: What AI Really Means For Health Communications

While AI is reshaping frontline healthcare at pace—spotting cancers, triaging patients, and summarising records—its uptake in health communications remains tentative. Agencies are experimenting behind the scenes, but real integration is...

Fox&Cat

- PMLiVE

Novartis to invest $23bn into US-based infrastructure over next five years

The commitment will allow the company to produce 100% of its key medicines end-to-end in the US

- PMLiVE

Johnson & Johnson’s subcutaneous Rybrevant granted EC approval to treat NSCLC

It is hoped that the formulation will improve the treatment experience for patients

Bayer symbol

Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links